A Study of Guselkumab After Switching From Ustekinumab in Participants With Moderate to Severe Psoriasis
ConditionPsoriasis
Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age18+
SponsorJanssen-Cilag Ltd.
About this trial
The purpose of this study is to assess the effectiveness and safety of guselkumab following a switch from ustekinumab or an ustekinumab biosimilar in participants with moderate to severe psoriasis, a chronic inflammatory skin disease characterized by erythematous, scaly plaques that may be associated with pain and pruritus, in routine clinical practice.
Eligibility criteria
Qualifiers
Must have a confirmed diagnosis of moderate-to-severe plaque psoriasis requiring systemic treatment
Participants who are currently treated with Ustekinumab (either the originator or its biosimilar) and who are medically indicated to switch to Guselkumab
Participants who, based on the Investigator's decision, should initiate treatment with Guselkumab
Participants must understand and be willing and able to answer patient-reported outcomes (PROs)
Disqualifiers
Contraindication or hypersensitivity to Guselkumab or any ingredient in the injection solution/liquid
Pregnancy or breastfeeding
Currently enrolled in an interventional study
Currently enrolled in an observational study sponsored or managed by a Janssen company
Trial design
Treatments tested in this trial
- Not listed
Trial groups
200 Participants
are grouped into 1 trial groupSponsors and collaborators
Source ClinicalTrials.gov